Author(s):
Desi Eka Putri, Dachriyanus Hamidi, Yozarwardi Usama Putra, Almahdy Almahdy, Najihah Mohd. Hashim, Fatma Sri Wahyuni
Email(s):
desi.eka@pom.go.id , dachriyanus@phar.unand.ac.id , yozarwardi.usama1234@gmail.com , almahdya@phar.unand.ac.id , najihahmh@um.edu.my , fatmasriwahyuni@phar.unand.ac.id
DOI:
10.52711/0974-360X.2026.00282 
Address:
Desi Eka Putri1,2, Dachriyanus Hamidi2, Yozarwardi Usama Putra3, Almahdy Almahdy4, Najihah Mohd. Hashim5, Fatma Sri Wahyuni3*
1Postgraduate Student, Faculty of Pharmacy, Universitas Andalas, Padang 25163, Indonesia.
2Indonesian Food and Drug Administration (BPOM), Jakarta 10560, Indonesia.
3Faculty of Pharmacy, Universitas Andalas, Padang 25163, Indonesia.
4Department of Forestry, West Sumatra Province, Padang 25114, Indonesia.
5Faculty of Pharmacy, Universiti Malaya, Kuala Lumpur 50603, Malaysia.
*Corresponding Author
Published In:
Volume - 19,
Issue - 5,
Year - 2026
ABSTRACT:
Taxus sumatrana (Miq.) de Laub. has a long history of use in traditional medicine across various regions of Indonesia for treating conditions related to cancer. However, scientific evidence supporting its efficacy and safety remains limited. Previous studies have reported that ethanol extracts of the bark, leaves, and shoots of T. sumatrana demonstrate significant cytotoxic effects on different cancer cell lines. Nevertheless, the selectivity of these extracts toward cancer cells compared to normal cells has not been established. This study focused on assessing and comparing the selectivity index (SI) of ethanol extracts derived from the bark, leaves, and shoots of T. sumatrana against breast cancer (T47D, MCF-7/HER-2) and cervical cancer cell lines (HeLa), using Vero cells as a normal cell model. The cytotoxic activity of each extract was evaluated using the MTT assay. IC50 values were calculated for both cancerous and normal cell lines, and the SI was determined by dividing the IC50 value in Vero cells by that in each cancer cell line. High-performance liquid chromatography (HPLC) was employed to quantify the paclitaxel content in each extract. All three extracts demonstrated cytotoxic effects on cancer cells and lower toxicity toward Vero cells, with SI values exceeding 1. The shoot extract exhibited the highest SI in T47D cells (21.92), followed by the leaf extract in T47D cells (17.67) and in HeLa cells (13.53). The bark extract showed the highest paclitaxel content, while the shoot and leaf extracts contained lower levels. These findings indicate that all T. sumatrana extracts exhibited favorable selectivity toward the tested breast and cervical cancer cell lines in vitro, with the shoot and leaf extracts yielding the highest SI values. Further studies are needed to isolate the active compounds responsible for this activity, elucidate their mechanisms of action, and evaluate their safety and efficacy using in vivo models.
Cite this article:
Desi Eka Putri, Dachriyanus Hamidi, Yozarwardi Usama Putra, Almahdy Almahdy, Najihah Mohd. Hashim, Fatma Sri Wahyuni. Selectivity Index Profile of Taxus sumatrana (Miq.) de Laub. Extracts in Breast and Cervical Cancer Cells. Research Journal Pharmacy and Technology. 2026;19(5):1969-6. doi: 10.52711/0974-360X.2026.00282
Cite(Electronic):
Desi Eka Putri, Dachriyanus Hamidi, Yozarwardi Usama Putra, Almahdy Almahdy, Najihah Mohd. Hashim, Fatma Sri Wahyuni. Selectivity Index Profile of Taxus sumatrana (Miq.) de Laub. Extracts in Breast and Cervical Cancer Cells. Research Journal Pharmacy and Technology. 2026;19(5):1969-6. doi: 10.52711/0974-360X.2026.00282 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-5-3
REFERENCES:
1. Xu Y, Gong M, Wang Y, Yang Y, Liu S, Zeng Q. Global trends and forecasts of breast cancer incidence and deaths. Sci Data. 2023; 10(334): 1-10. doi:10.1038/s41597-023-02253-5
2. WHO. World Health Statistics 2024: Monitoring Health for the SDGs, Sustainable Development Goals.; 2024.
3. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(February): 229-263. doi:10.3322/caac.21834
4. Anand U, Dey A, Singh AK, et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023; 11: 1367-1401. doi:10.1016/j.gendis.2022.02.007
5. Llamas-ramos I, Alvarado-omenat JJ, Llamas-ramos R. Quality of life and side effects management in cancer treatment - a cross sectional study. Int J Environ Res Public Health. 2023; 20(1708):1-10.
6. Blayney DW, Schwartzberg L. Chemotherapy-induced neutropenia and emerging agents for prevention and treatment. Cancer Treat Rev. 2022; 109(June):1-10. doi:10.1016/j.ctrv.2022.102427
7. Ismail U, Killeen RB. Taxane Toxicity.; 2023. http://www.ncbi.nlm.nih.gov/pubmed/33429249%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC9457747
8. Takara K, Sakaeda T, Yagami T, et al. Cytotoxic Effects of 27 Anticancer Drugs in HeLa and MDR1-Overexpressing Derivative Cell Lines. Biol Pharm Bull. 2002;25(6):771-778.
9. Ma Y, Grootaert MOJ, Sewduth RN. Cardiotoxicity of chemotherapy: a multi-OMIC perspective. Xenobiotics. 2025;15(9):1-22.
10. Lai E, Persano M, Dubois M, et al. Drug-related toxicity in breast cancer patients: a new path towards tailored treatment? Precis Cancer Med. 2022; 5(15): 21-38. doi:10.21037/pcm-21-38
11. Thalkari AB, Karwa PN, Zambare KK, Tour NS, Chopane PS. Paclitaxel against cancer: A new trademarked drug. Res J Pharmacogn Phytochem. 2019; 11(3): 123-128. doi:10.5958/0975-4385.2019.00021.9
12. Manzari-Tavakoli A, Babajani A, Tavakoli MM, Safaeinejad F, Jafari A. Integrating natural compounds and nanoparticle-based drug delivery systems: a novel strategy for enhanced efficacy and selectivity in cancer therapy. Cancer Med. 2024; 13(e7010):1-19. doi:10.1002/cam4.7010
13. Khasanah U, Shalas AF, Rifai B, Ihsan P, Ayu L, Wulandari A. Evaluation of Selectivity Index and Phytoconstituents Profile of Various Extracts from the Stem of Strychnos lucida. Pharmacognosy Res. 2023; 15(4): 733-750. doi:10.5530/pres.15.4.078
14. Faundes-gandolfo N, Jara-gutiérrez C, Párraga M, et al. Kalanchoe pinnata (Lam.) Pers. Leaf ethanolic extract exerts selective anticancer activity through ROS-induced apoptotic cell death in human cancer cell lines. BMC Complement Med Ther. 2024;24(269):1-14.
15. Indrayanto G, Putra GS, Suhud F. Validation of in-vitro bioassay methods: Application in herbal drug. In: Al-Majed AA, ed. Profiles of Drug Substances, Excipients and Related Methodology. Vol 46. Academic Press; 2021:273-307.
16. Klimek K, Tyskiewicz K, Miazga-Karska M, Debczak A, Rój E, Ginalska G. Bioactive compounds obtained from polish “Marynka” hop anti-proliferative activities in vitro. Molecules. 2021; 26(2366): 1-18.
17. Wang X, Gigant B, Zheng X, Chen Q. Microtubule‐targeting agents for cancer treatment: Seven binding sites and three strategies. MedComm – Oncol. 2023; 2(April):1-20. doi:10.1002/mog2.46
18. Bozdaganyan M, Fedorov V, Kholina E, Kovalenko I, Gudimchuk N, Orekhov P. Exploring tubulin-paclitaxel binding modes through extensive molecular dynamics simulations. Sci Rep. 2025; 15(8378): 1-16.
19. Lixian S, Xiaoqian Y, Luyan G, Lizhi Z, Rui D. Risk factors of paclitaxel-induced peripheral neuropathy in patients with breast cancer: a prospective cohort study. Oncology. 2024; 14(March): 1-11. doi:10.3389/fonc.2024.1327318
20. Lykkegaard N, Timm S, Bennedsgaard K, et al. Chronic chemotherapy-induced peripheral neuropathy and pain following paclitaxel versus docetaxel in breast cancer survivors : A cross-sectional study Michigan Neuropathy Screen Instrument questionnaire. The Breast. 2025; 80(104424): 1-8. doi:10.1016/j.breast.2025.104424
21. Gaumond SI, Lee KJ, Warp P V, Kamholtz I, Dreifus EM, Jimenez JJ. Parallel toxicities: a comparative analysis of chemotherapy-induced neutropenia and alopecia. Cancers (Basel). 2025; 17(1163): 1-20.
22. Swain B, Singh H, Jain R, Mishra S. Association of febrile neutropenia with chemotherapeutic agents in malignancies. Asian J Pharm Clin Res. 2023; 16(8): 76-79.
23. Tran X, Mulac D, Langer K. Investigating the selectivity of the targeting properties of trastuzumab-bound nanoparticles to HER2/neu positive cells in co-culture. J Drug Deliv Sci Technol. 2024; 100(106040): 1-10. doi:10.1016/j.jddst.2024.106040
24. Rubin E, Shan KS, Dalal S, et al. Molecular targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) genes across various cancers. Int J Mol Sci Rev. 2024; 25(1064): 1-46.
25. Kumari P, Singh A. Pharmacology of natural compounds found in clinical trials used for ameliorating/preventing cancer. Asian J Pharm Anal. 2025; 14(3): 195-200. doi:10.52711/2231-5675.2024.00035
26. Hao DC. Taxaceae and Cephalotaxaceae: Biodiversity, Chemodiversity, and Pharmacotherapy. (Jones G, ed.). Academic Press; 2021.
27. Wahyuni FS, Putri DE, Putra YU, Hamidi D. Cytotoxic activity of Taxus sumatrana (Miq.) de Laub. bark, leaves, and shoots on HELA, T47D, and MCF-7/HER2 cell lines. Int J Appl Pharm. 2024; 16(1): 93-98. doi:https://dx.doi.org/10.22159/ijap.2024.v16s1.23
28. Putri DE, Almahdy A, Hamidi D, Wahyuni FS. The potential of Taxus sumatrana as a candidate for cancer therapy. J Food Med Plants. 2023; 4(1): 1-7. doi:https://doi.org/10.25077/jfmp.4.1.1-7.2023
29. Popova M, Bankova V. Contemporary methods for the extraction and isolation of natural products. BMC Chem. 2023; 17(1): 1-2. doi:10.1186/s13065-023-00960-z
30. Khanal S. Qualitative and quantitative phytochemical screening of Azadirachta indica Juss. plant parts. Int J Appl Sci Biotechnol. 2021; 9(2): 122-127. doi:10.3126/ijasbt.v9i2.38050
31. Depkes RI. Farmakope Indonesia Edisi IV.; 1995.
32. Sheetal M. Development and Characterization of Docetaxel Encapsulated pH-Sensitive Liposomes for Cancer Therapy. Res J Pharm Dos Forms Technol. 2013; 5(3): 151-160.
33. Tronina T, Bartmanska A, Popłonski J, et al. Prenylated flavonoids with selective toxicity against human cancers. Int J Mol Sci. 2023; 24(7408): 1-12.
34. Pieme AA, Kumar GG, Dongmo SS, et al. Antiproliferative activity and induction of apoptosis by Annona muricata (Annonaceae) extract on human cancer cells. BMC Complement Altern Med. 2014; 14(1): 1-10. doi:10.1186/1472-6882-14-516
35. Soni A, Femida P, Sharma P. In-vitro cytotoxic activity of plant saponin extracts on breast cancer cell-line. Res J Pharmacogn Phytochem. 2017; 9(1): 17-22. doi:10.5958/0975-4385.2017.00003.6
36. Bhukya B, Lingabathula H, Yellu N. Evaluation of anti cancer activity of Kydia calycina Roxb. leaf extract on different cancer cell lines. Res J Pharmacogn Phytochem. 2017; 9(4): 197-202. doi:10.5958/0975-4385.2017.00036.X
37. Kangralkar VA, Kulkarni AR. In vitro cytotoxic activity of alcoholic extract of Aristolochia indica. Res J Pharm Technol. 2013; 6(11): 1240-1241.
38. Khare E, Sharma A, Chowdhury A, Narwariya SS. Potential of natural products for chemoprevention of breast cancer. Res J Pharmacogn Phytochem. 2023; 15(4): 305-310. doi:10.52711/0975-4385.2023.00048
39. Riffi O, Kachmar MR, M’hamdi Z, Fliou J, Chakir S, Amechrouq A. Study of the chemical composition and evaluation of the antioxidant and antimicrobial activity of Taxus baccata L. Arab J Chem. 2023;16(105334):1-6. doi:10.1016/j.arabjc.2023.105334
40. Foa R, Norton L, Seidman A. Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. Int J Clin Lab Res. 1994; 24(1): 6-14. doi:10.1007/BF02592403
41. Jiménez-González V, Benítez G, Pastor JE, López-Lázaro M, Alderón-Montaño JM. Evaluation of anticancer activity of 76 plant species collected in Andalusia (Spain) against lung cancer cells. Plants. 2023; 12(3275): 1-17.
42. Calderón-Montaño JM, Martínez-Sánchez SM, Jiménez-González V, et al. Screening for selective anticancer activity of 65 extracts of plants collected in Western Andalusia, Spain. Plants. 2021; 10(2193): 1-19.
43. Fisall UFM, Ismail NZ, Adebayo IA, Arsad H. Dichloromethane fraction of Moringa oleifera leaf methanolic extract selectively inhibits breast cancer cells (MCF7) by induction of apoptosis via upregulation of Bax, p53 and caspase 8 expressions. Mol Biol Rep. 2021; 481: 4465–4475. doi:https://doi.org/10.1007/s11033-021-06466-y
44. Furqan M, Wahyuni FS, Susanti M, Hamidi D. Evaluation of Garcinia cowa leaf extract as a potential anticancer agent: cytotoxicity, selectivity, and apoptotic effects on MCF-7/HER-2 cells. Trop J Nat Prod Res. 2025; 9(2): 846-852.
45. Rodríguez-Garza NE, Quintanilla-licea R, Romo-Sáenz CI, et al. In vitro biological activity and lymphoma cell growth inhibition by selected Mexican medicinal plants. Life. 2023; 13(958): 1-14.
46. Badmus JA, Ekpo OE, Hussein AA, Meyer M, Hiss DC. Cytotoxic and cell cycle arrest properties of two steroidal alkaloids isolated from Holarrhena floribunda (G. Don) T. Durand and Schinz leaves. BMC Complement Altern Med. 2019; 9(1112): 1-9.
47. Duarte D, Nunes M, Ricardo S, Vale N. Combination of antimalarial and CNS drugs with antineoplastic agents in MCF-7 breast and HT-29 colon cancer cells : biosafety evaluation and mechanism of cction. Biomolecules. 2022;12(1490):2-28.
48. Widiandani T, Susilawati D, Pratama MRF, Tri PB, Siswandono S, Ifadotunnikmah F. The potency of 4-methyl-3-benzoyl allylthiourea as anti-breast cancer: Molecular dynamic simulation, cytotoxic activity, and its selectivity index. Res J Pharm Technol. 2025; 18(3): 1182-1188. doi:10.52711/0974-360X.2025.00171
49. Hospital TA. Apoptosis induced by low-dose paclitaxel is associated with p53 upregulation in nasopharyngeal carcinoma cells. Int J Cancer. 2002; 97: 168-172.
50. Vikhanskaya F, Vignati S, Beccaglia P, et al. Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp Cell Res. 1998;241:96-101.
51. Lan Y yan, Cheng T chih, Lee Y ping, Wang C yih, Huang BM. Paclitaxel induces human KOSC3 oral cancer cell apoptosis through caspase pathways. Biocell. 2024; 48(7): 1047-1054.
52. Guntur VP, Waldrep JC, Guo JJ, Selting KIM, Dhand R. Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. Anticancer Res. 2010; 30: 3557-3564.
53. Klein I, Lehmann HC. Pathomechanisms of paclitaxel-induced peripheral neuropathy. Toxics. 2021; 9(229): 1-13.
54. Skverchinskaya E, Levdarovich N, Ivanov A, Mindukshev I, Bukatin A. Anticancer drugs paclitaxel, carboplatin, doxorubicin, and cyclophosphamide alter the biophysical characteristics of red blood cells, in vitro. Biology (Basel). 2023; 12(230): 1-22.
55. Ahmed OS, Mahadevia H, Manochakian R, et al. Case reports a case of full recovery from prolonged cardiac arrest after infusion with paclitaxel and pembrolizumab. Case Rep Oncol. 2022; 15: 1063-1073. doi:10.1159/000527205
56. Kumari P, Sharma D, Singh A. In-vivo studies conducted following the success in-vitro and dissemination of anticancer clinical trials. Asian J Res Chem. 2024; 17(1): 50-54. doi:10.52711/0974-4150.2024.00010
57. Kurniawan R, Sukrasno S, Ashari A, Suhartati T. Diving into paclitaxel: isolation and screening content from Taxus sumatrana at Singgalang Conservation Center, West Sumatra. Nat Prod Res. 2024; (February): 2-5. doi:10.1080/14786419.2024.2312540
58. Kitagawa I, Mahmud T, Kobayashi M, Roemantyo H, Shibuya H. Taxol and its related taxoids from the needles of Taxus sumatrana. Chem Pharm Bull. 1995; 43(2). doi:10.1248/cpb.43.365
59. Shen YC, Wang SS, Pan YL, et al. New taxane diterpenoids from the leaves and twigs of Taxus sumatrana. J Nat Prod. 2002; 65(12). doi:10.1021/np0202273
60. Shen YC, Pan YL, Lo KL, et al. New taxane diterpenoids from Taiwanese Taxus sumatrana. Chem Pharm Bull. 2003; 51(7). doi:10.1248/cpb.51.867
61. Shen YC, Cheng KC, Lin YC, et al. Three new taxane diterpenoids from Taxus sumatrana. J Nat Prod. 2005; 68(1). doi:10.1021/np040132w
62. Shen YC, Lin YS, Cheng Y Bin, et al. Novel taxane diterpenes from Taxus sumatrana with the first C-21 taxane ester. Tetrahedron. 2005; 61(5). doi:10.1016/j.tet.2004.10.110
63. Shen YC, Hsu SM, Lin YS, et al. New bicyclic taxane diterpenoids from Taxus sumatrana. Chem Pharm Bull. 2005; 53(7). doi:10.1248/cpb.53.808
64. Shen YC, Lin YS, Hsu SM, et al. Tasumatrols P-T, five new taxoids from Taxus sumatrana. Helv Chim Acta. 2007; 90(7). doi:10.1002/hlca.200790133
65. Shen YC, Wang SS, Chien C Te, Kuo YH, Khalil AT. Tasumatrols U-Z, taxane diterpene esters from Taxus sumatrana. J Nat Prod. 2008; 71(4). doi:10.1021/np078016r
66. Wang SS, Abd El-Razek MH, Chen YG, et al. abeo-taxane diterpenoids from the Taiwanese yew Taxus sumatrana. Chem Biodivers. 2009;6(12). doi:10.1002/cbdv.200900003
67. Luh LJ, Abd El-Razek MH, Liaw CC, et al. Tri- and bicyclic taxoids from the Taiwanese yew Taxus sumatrana. Helv Chim Acta. 2009; 92(7): 1349-1358. doi:10.1002/hlca.200900022
68. Kuo WL, Chen FC, Chen KJ, Chen JJ. Taxusumatrin, a new taxoid from the stem bark of Taxus sumatrana. Chem Nat Compd. 2015; 51(3). doi:10.1007/s10600-015-1308-6
69. Singh N, Zalma K, Khatri M, Ven P, Singh A. Screening and validation of natural products for drug discovery: Key points and approaches. Asian J Pharm Res. 2024; 14(2): 162-168. doi:10.52711/2231-5691.2024.00027